Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer
PHASE1CompletedINTERVENTIONAL
Enrollment
31
Participants
Timeline
Start Date
June 30, 2013
Primary Completion Date
November 30, 2015
Study Completion Date
November 30, 2015
Conditions
Metastatic Breast CancerColorectal CancerProstate Cancer
Interventions
DRUG
Foxy-5
Trial Locations (1)
2730
Oncology Department, Herlev Hospital, Herlev
All Listed Sponsors
lead
WntResearch AB
INDUSTRY
NCT02020291 - Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer | Biotech Hunter | Biotech Hunter